サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1500815

肺線維症治療市場：世界の産業分析、規模、シェア、成長、動向、2024年～2033年予測

Pulmonary Fibrosis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 277 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺線維症治療市場：世界の産業分析、規模、シェア、成長、動向、2024年～2033年予測
出版日: 2024年06月20日
発行: Persistence Market Research
ページ情報: 英文 277 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、肺線維症治療の世界市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・課題などの主要な市場ダイナミクスを詳細に分析し、市場情勢に関する貴重な洞察を提供しています。この調査レポートは、2024年から2033年までの肺線維症治療市場の成長軌道を予測する独占データと統計を提供しています。

主な洞察

  • 市場規模（2024E）：31億米ドル
  • 市場予測値（2033F）：56億米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：6.8%

肺線維症治療市場- レポート範囲：

肺線維症治療は、線維化肺疾患の進行を管理し、逆転させる可能性を目的とした様々な治療アプローチを扱う。これらの治療には、薬理学的介入、酸素療法、肺リハビリテーション、重症例では肺移植などが含まれます。同市場は、病院、専門クリニック、肺リハビリテーションセンター、在宅医療の現場で、抗線維化薬、免疫抑制薬、新規生物製剤などのさまざまな治療オプションを提供しています。

市場促進要因：

世界の肺線維症治療市場は、特発性肺線維症（IPF）やサルコイドーシスなどの呼吸器疾患の有病率の増加など、いくつかの要因によって牽引されています。高齢化人口の増加とそれに伴う慢性疾患の罹患率の増加が市場拡大に大きく寄与しています。薬剤開発の進展、特にピルフェニドンやニンテダニブのような抗線維化療法の出現は、患者の予後を改善する効果的な治療選択肢を提供することで市場の成長を後押ししています。さらに、医療従事者や患者の間で早期診断や治療開始に対する意識が高まっていることも、市場の需要を後押ししています。

市場抑制要因：

有望な成長が見込まれるもの、肺線維症治療市場は、高い治療費、限られた治療法しかないこと、医薬品承認のための厳しい規制要件などに関連する課題に直面しています。地域によっては経済的制約があり、ヘルスケアインフラが不十分なため、特に新興国では市場浸透の妨げとなっています。さらに、肺線維症の診断と管理は複雑であるため、専門的なヘルスケアの知識が必要となり、効果的な治療へのさらなる障壁となっています。

市場機会：

肺線維症治療市場は、新規治療ターゲットと個別化医療アプローチに焦点を当てた研究開発が進行中であることから、ビジネスチャンスに恵まれています。画像診断とバイオマーカー同定における技術革新は、疾患の検出とモニタリングを強化し、早期介入と個別化治療計画を促進します。製薬企業と学術研究機関の戦略的提携はイノベーションを促進し、画期的な治療法のイントロダクションを加速します。さらに、遠隔医療とデジタルヘルスソリューションの統合は、患者の専門的治療へのアクセスを拡大し、治療のアドヒアランスを向上させることで、市場の成長を刺激します。

本レポートで扱う主な質問

  • 肺線維症治療市場の世界的成長を促進する主な要因は何か？
  • さまざまなヘルスケア環境において、どのような治療様式や治療クラスが採用を促進しているか？
  • 技術の進歩は肺線維症治療市場の競合情勢をどのように変えているか？
  • 肺線維症治療市場に貢献している主要プレイヤーは誰で、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の肺線維症治療市場における新たな動向と将来展望は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 重要成功要因

  • パイプライン評価
  • 疾病疫学
  • 市場プレーヤーの主なプロモーション戦略
  • 地域別の採用/適応分析
  • 規制シナリオ
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 治療タイプ別収益
    • 適応症別収益
    • 流通チャネル別収益
    • 地域別収益
  • 2024年の市場シナリオ

第7章 世界の肺線維症治療市場の需要（価値または規模）分析

  • 2019年～2023年の市場金額の歴史的分析
  • 現在および将来の市場金額予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対的な$機会分析

第8章 世界の肺線維症治療市場分析（治療タイプ別）

  • イントロダクション/主な調査結果
  • 2019年～2023年の治療タイプ別市場規模の歴史的分析
  • 現在および将来の市場規模の分析と予測、治療タイプ別、2024年～2033年
    • 単独療法
      • ピルフェニドン療法
      • ニンテダニブ療法
      • コルチコステロイド療法
    • 併用療法
      • ピルフェニドンとコルチコステロイド
      • ニンテダニブとコルチコステロイド
      • ピルフェニドンと鎮咳薬
      • その他
    • 治療
  • 治療タイプ別の市場の魅力分析

第9章 世界の肺線維症治療薬市場分析（適応症別）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析、適応症別、2019年～2023年
  • 現在および将来の市場規模の分析と予測、適応症別、2024年～2033年
    • 特発性肺線維症（IPF）
    • 家族性PF
    • その他
  • 適応症別の市場の魅力分析

第10章 世界の肺線維症治療市場分析（流通チャネル別）

  • イントロダクション/主な調査結果
  • 過去の市場規模分析、流通チャネル別、2019年～2023年
  • 現在および将来の市場規模の分析と予測、流通チャネル別、2024年～2033年
    • 病院薬局
    • 小売薬局
    • 通信販売薬局
  • 流通チャネル別市場の魅力分析

第11章 地域別肺線維症治療市場分析

  • イントロダクション
  • 地域別市場規模の過去分析、2019年～2023年
  • 現在および将来の市場規模の地域別分析と予測、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ（中東・アフリカ）
  • 地域別市場の魅力分析

第12章 北米の肺線維症治療市場分析

第13章 ラテンアメリカの肺線維症治療市場分析

第14章 欧州の肺線維症治療市場分析

第15章 東アジアの肺線維症治療市場分析

第16章 南アジアの肺線維症治療市場分析

第17章 オセアニアの肺線維症治療市場

第18章 中東およびアフリカ（中東・アフリカ）の肺線維症治療市場分析

第19章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • F. Hoffman-La Roche Ltd.
    • Boehringer Ingelheim
    • International GmbH
    • Cipla Ltd（Cipla）
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • FibroGen Inc.,
    • Galecto, Inc.

第21章 使用される仮定と頭字語

第22章 調査手法

目次
Product Code: PMRREP30070

Persistence Market Research has recently released a comprehensive report on the global market for pulmonary fibrosis treatment. The report provides a detailed analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering valuable insights into the market landscape. This research publication offers exclusive data and statistics projecting the growth trajectory of the pulmonary fibrosis treatment market from 2024 to 2033.

Key Insights:

  • Market Size (2024E): USD 3.1 Billion
  • Projected Market Value (2033F): USD 5.6 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 6.8%

Pulmonary Fibrosis Treatment Market - Report Scope:

Pulmonary fibrosis treatment addresses a range of therapeutic approaches aimed at managing and potentially reversing the progression of fibrotic lung diseases. These treatments include pharmacological interventions, oxygen therapy, pulmonary rehabilitation, and in severe cases, lung transplantation. The market serves hospitals, specialty clinics, pulmonary rehabilitation centers, and homecare settings, offering a variety of treatment options such as antifibrotic drugs, immunosuppressants, and novel biologics.

Market Growth Drivers:

The global pulmonary fibrosis treatment market is driven by several factors, including increasing prevalence of respiratory disorders such as idiopathic pulmonary fibrosis (IPF) and sarcoidosis. Growing aging population and associated higher incidence of chronic diseases contribute significantly to market expansion. Advances in drug development, particularly the emergence of antifibrotic therapies like pirfenidone and nintedanib, bolster market growth by providing effective treatment options with improved patient outcomes. Additionally, rising awareness about early diagnosis and treatment initiation among healthcare providers and patients propels market demand.

Market Restraints:

Despite promising growth prospects, the pulmonary fibrosis treatment market faces challenges related to high treatment costs, limited availability of curative treatments, and stringent regulatory requirements for drug approval. Economic constraints in some regions, coupled with insufficient healthcare infrastructure, hinder market penetration, especially in developing countries. Furthermore, the complexity of diagnosing and managing pulmonary fibrosis necessitates specialized healthcare expertise, posing additional barriers to effective treatment.

Market Opportunities:

The pulmonary fibrosis treatment market presents opportunities driven by ongoing research and development initiatives focused on novel therapeutic targets and personalized medicine approaches. Technological innovations in diagnostic imaging and biomarker identification enhance disease detection and monitoring, facilitating early intervention and personalized treatment plans. Strategic collaborations between pharmaceutical companies and academic research institutions foster innovation and accelerate the introduction of breakthrough therapies. Moreover, the integration of telemedicine and digital health solutions expands patient access to specialized care and improves treatment adherence, thereby stimulating market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the pulmonary fibrosis treatment market globally?
  • Which treatment modalities and therapeutic classes are driving adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the pulmonary fibrosis treatment market?
  • Who are the key players contributing to the pulmonary fibrosis treatment market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global pulmonary fibrosis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pulmonary fibrosis treatment market, including major pharmaceutical companies and biotechnology firms, focus on expanding their product portfolios through strategic acquisitions, partnerships, and licensing agreements. Companies invest heavily in clinical trials to demonstrate efficacy and safety profiles of new treatments, ensuring regulatory approval and market acceptance. Furthermore, patient education initiatives and advocacy efforts by healthcare organizations raise awareness about pulmonary fibrosis, driving early diagnosis and treatment initiation.

Key Companies Profiled:

  • F. Hoffman - La Roche Ltd.
  • Boehringer Ingelheim
  • International GmbH
  • Cipla Ltd (Cipla)
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • FibroGen Inc.,
  • Galecto, Inc.

Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research

By Therapy Type:

  • Monotherapy
  • Combination Therapy
  • Symptomatic Treatment

By Indication:

  • Idiopathic Pulmonary Fibrosis (IPF)
  • Familial PF
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Pipeline Assessment
  • 4.2. Disease Epidemiology
  • 4.3. Key Promotional Strategies by Market Players
  • 4.4. Adoption/ Indication Analysis by region
  • 4.5. Regulatory Scenario
  • 4.6. PESTEL Analysis
  • 4.7. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Growth of Pharmaceutical Sector in Emerging nations
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Top Companies Historical Growth
    • 5.2.2. Growing Demand for Pulmonary Fibrosis Treatment
    • 5.2.3. Pipeline assessments
    • 5.2.4. Increasing Investment in Pharmaceutical
    • 5.2.5. Costs of Pulmonary Fibrosis Treatment
    • 5.2.6. Adoption of Pulmonary Fibrosis Treatment
    • 5.2.7. Rise in Sales of Medical Devices
    • 5.2.8. Regulatory Framework
    • 5.2.9. Rising Disease Epidemic
    • 5.2.10. Launch of New Drug
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Therapy Type
    • 6.1.2. Revenue By Indication
    • 6.1.3. Revenue By Distribution Channel
    • 6.1.4. Revenue By Region
  • 6.2. 2024 Market Scenario

7. Global Pulmonary Fibrosis Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Therapy Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Therapy Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy Type, 2024-2033
    • 8.3.1. Monotherapy
      • 8.3.1.1. Pirfenidone Therapy
      • 8.3.1.2. Nintedanib Therapy
      • 8.3.1.3. Corticosteroids Therapy
    • 8.3.2. Combination Therapy
      • 8.3.2.1. Pirfenidone & Corticosteroid
      • 8.3.2.2. Nintedanib & Corticosteroid
      • 8.3.2.3. Pirfenidone & Antitussive
      • 8.3.2.4. Others
    • 8.3.3. Symptomatic Treatment
  • 8.4. Market Attractiveness Analysis By Therapy Type

9. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Indication

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
    • 9.3.1. Idiopathic Pulmonary Fibrosis (IPF)
    • 9.3.2. Familial PF
    • 9.3.3. Others
  • 9.4. Market Attractiveness Analysis By Indication

10. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Mail Order Pharmacy
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Therapy Type
    • 12.3.3. By Indication
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Therapy Type
    • 12.4.3. By Indication
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Pulmonary Fibrosis Treatment Market Analysis
      • 12.8.1.1. .Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Therapy Type
        • 12.8.1.2.2. By Indication
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Pulmonary Fibrosis Treatment Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Therapy Type
        • 12.8.2.2.2. By Indication
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Therapy Type
    • 13.3.3. By Indication
    • 13.3.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Therapy Type
    • 13.4.3. By Indication
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Pulmonary Fibrosis Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Therapy Type
        • 13.8.1.2.2. By Indication
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Pulmonary Fibrosis Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Therapy Type
        • 13.8.2.2.2. By Indication
        • 13.8.2.2.3. By Distribution Channel
    • 13.8.3. Argentina Pulmonary Fibrosis Treatment Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Therapy Type
        • 13.8.3.2.2. By Indication
        • 13.8.3.2.3. By Distribution Channel

14. Europe Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. Russia
      • 14.3.1.7. BENELUX
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Therapy Type
    • 14.3.3. By Indication
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Therapy Type
    • 14.4.3. By Indication
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Therapy Type
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Therapy Type
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Therapy Type
        • 14.8.3.2.2. By Indication
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.4.2.1. By Therapy Type
        • 14.8.4.2.2. By Indication
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.5.2.1. By Therapy Type
        • 14.8.5.2.2. By Indication
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. Russia Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.6.2.1. By Therapy Type
        • 14.8.6.2.2. By Indication
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. BENELUX Pulmonary Fibrosis Treatment Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.7.2.1. By Therapy Type
        • 14.8.7.2.2. By Indication
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Therapy Type
    • 15.3.3. By Indication
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Therapy Type
    • 15.4.3. By Indication
    • 15.4.4. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Pulmonary Fibrosis Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Therapy Type
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Pulmonary Fibrosis Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Therapy Type
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Pulmonary Fibrosis Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Therapy Type
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Therapy Type
    • 16.3.3. By Indication
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Therapy Type
    • 16.4.3. By Indication
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Pulmonary Fibrosis Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Therapy Type
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Pulmonary Fibrosis Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Therapy Type
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Pulmonary Fibrosis Treatment Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Therapy Type
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Pulmonary Fibrosis Treatment Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Therapy Type
        • 16.8.4.2.2. By Indication
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Pulmonary Fibrosis Treatment Market 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Therapy Type
    • 17.3.3. By Indication
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Therapy Type
    • 17.4.3. By Indication
    • 17.4.4. By Distribution Channel
  • 17.5. Key Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Australia Pulmonary Fibrosis Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Therapy Type
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Distribution Channel
    • 17.8.2. New Zealand Pulmonary Fibrosis Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Therapy Type
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Pulmonary Fibrosis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Turkey
      • 18.3.1.2. GCC Countries
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of MEA
    • 18.3.2. By Therapy Type
    • 18.3.3. By Indication
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Therapy Type
    • 18.4.3. By Indication
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Turkey Pulmonary Fibrosis Treatment Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Therapy Type
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. GCC Countries Pulmonary Fibrosis Treatment Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Therapy Type
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Pulmonary Fibrosis Treatment Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.3.2.1. By Therapy Type
        • 18.8.3.2.2. By Indication
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Pulmonary Fibrosis Treatment Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.4.2.1. By Therapy Type
        • 18.8.4.2.2. By Indication
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis by Tier of Companies
  • 19.2. Market Share Analysis of Top Players
  • 19.3. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Deep Dive
    • 20.2.1. F. Hoffman - La Roche Ltd.
      • 20.2.1.1. Overview
      • 20.2.1.2. Service Portfolio
      • 20.2.1.3. Key Financials
      • 20.2.1.4. Sales Footprint
      • 20.2.1.5. Strategy Overview
        • 20.2.1.5.1. Marketing Strategy
        • 20.2.1.5.2. Product Strategy
        • 20.2.1.5.3. Channel Strategy
    • 20.2.2. Boehringer Ingelheim
      • 20.2.2.1. Overview
      • 20.2.2.2. Service Portfolio
      • 20.2.2.3. Key Financials
      • 20.2.2.4. Sales Footprint
      • 20.2.2.5. Strategy Overview
        • 20.2.2.5.1. Marketing Strategy
        • 20.2.2.5.2. Product Strategy
        • 20.2.2.5.3. Channel Strategy
    • 20.2.3. International GmbH
      • 20.2.3.1. Overview
      • 20.2.3.2. Service Portfolio
      • 20.2.3.3. Key Financials
      • 20.2.3.4. Sales Footprint
      • 20.2.3.5. Strategy Overview
        • 20.2.3.5.1. Marketing Strategy
        • 20.2.3.5.2. Product Strategy
        • 20.2.3.5.3. Channel Strategy
    • 20.2.4. Cipla Ltd (Cipla)
      • 20.2.4.1. Overview
      • 20.2.4.2. Service Portfolio
      • 20.2.4.3. Key Financials
      • 20.2.4.4. Sales Footprint
      • 20.2.4.5. Strategy Overview
        • 20.2.4.5.1. Marketing Strategy
        • 20.2.4.5.2. Product Strategy
        • 20.2.4.5.3. Channel Strategy
    • 20.2.5. Gilead Sciences, Inc.
      • 20.2.5.1. Overview
      • 20.2.5.2. Service Portfolio
      • 20.2.5.3. Key Financials
      • 20.2.5.4. Sales Footprint
      • 20.2.5.5. Strategy Overview
        • 20.2.5.5.1. Marketing Strategy
        • 20.2.5.5.2. Product Strategy
        • 20.2.5.5.3. Channel Strategy
    • 20.2.6. Bristol-Myers Squibb Company
      • 20.2.6.1. Overview
      • 20.2.6.2. Service Portfolio
      • 20.2.6.3. Key Financials
      • 20.2.6.4. Sales Footprint
      • 20.2.6.5. Strategy Overview
        • 20.2.6.5.1. Marketing Strategy
        • 20.2.6.5.2. Product Strategy
        • 20.2.6.5.3. Channel Strategy
    • 20.2.7. FibroGen Inc.,
      • 20.2.7.1. Overview
      • 20.2.7.2. Service Portfolio
      • 20.2.7.3. Key Financials
      • 20.2.7.4. Sales Footprint
      • 20.2.7.5. Strategy Overview
        • 20.2.7.5.1. Marketing Strategy
        • 20.2.7.5.2. Product Strategy
        • 20.2.7.5.3. Channel Strategy
    • 20.2.8. Galecto, Inc.
      • 20.2.8.1. Overview
      • 20.2.8.2. Service Portfolio
      • 20.2.8.3. Key Financials
      • 20.2.8.4. Sales Footprint
      • 20.2.8.5. Strategy Overview
        • 20.2.8.5.1. Marketing Strategy
        • 20.2.8.5.2. Product Strategy
        • 20.2.8.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology